Carcinoma: Page 3

NCCN updates pathology guidance in ovarian cancer
By LabPulse.com staff writers
In the new version, released on November 26, the guidelines now read:
December 1, 2019
2019 12 02 21 08 0302 Uterus Pelvic 400
Agilent's PD-L1 test gets OK for head, neck cancer in Europe
By LabPulse.com staff writers
The assay is approved for use as a companion diagnostic with the checkpoint inhibitor pembrolizumab (Keytruda, Merck), the company said in a statement. Keytruda is approved as a monotherapy or in combination with chemotherapy for the first-line treatment of metastatic or unresectable recurrent HNSCC in adults whose tumors express PD-L1 with a combined positive score of at least 1.
November 21, 2019
2019 11 22 18 03 1711 Eu Flag 400
Blood work tracks immunotherapy in GI cancers
By LabPulse.com staff writers
Hyperprogressive disease -- or rapid tumor expansion -- is an effect of immune checkpoint blockade drug therapy that has been getting more attention in recent years with the rising use of PD-1 inhibitors across tumor types. It is distinct from pseudoprogression, where there is tumor growth initially with immunotherapy treatment, but it is followed by a response.
July 25, 2019
2019 07 25 21 41 6277 Gastrointestinal Digestive System 400
Paige touts paper in Nature Medicine on AI for pathology
By LabPulse.com staff writers
In the paper, Chief Scientific Officer Thomas Fuchs, PhD, of Memorial Sloan Kettering Cancer Center and colleagues describe how a series of deep-learning algorithms for clinical decision support in pathology were developed with an automated training and testing technique. Fuchs is the senior author on the paper, with his student Gabriele Campanella as the first author.
July 17, 2019
2019 05 08 21 57 5547 Pathology Digital Workstation 400
ArcherDX teams with Ayala on companion tests
By LabPulse.com staff writers
The deal will involve the application of ArcherDX's proprietary Anchored Multiplexed PCR (AMP) platform to detect mutations in cancers targeted by drugs in Ayala's pipeline. Ayala's focus is on the development of oral gamma secretase inhibitors for cancers driven by the activation of the Notch signaling pathway. Gamma secretase is an enzyme that activates the Notch pathway, leading to tumorigenesis.
July 7, 2019
2019 07 08 18 08 5459 Men Working Business 400
Simple test of cystic fluid may help spare pancreatic surgeries
By Emily Hayes
In the blinded, retrospective analysis of 169 surgical samples from a range of tertiary referral centers, an enzyme-linked immunosorbent assay (ELISA) for the antibody Das-1 had an accuracy of 95% for identifying high-risk lesions and, therefore, which patients were most appropriate for surgery, reported a team led by Dr. Koushik Das, a Washington University gastroenterologist.
June 6, 2019
2019 06 06 18 07 0832 Pancreatic Cysts 20190606184938
Journal eyes liquid biopsy's promise with special edition
By LabPulse.com staff writers
Liquid biopsy detects markers for disease in bodily fluids less invasively than tissue biopsy. This makes it easier for physicians to monitor cancer progression in patients and to adjust treatment regimens as cancer cells develop resistance to existing therapies.
April 21, 2019
2019 04 22 18 53 8505 Lab Blood Liquid Samples 400
CAP, ASCO taking comments on guidelines for breast cancer receptor testing
By Brian Casey
More than 1 million women around the world are diagnosed with breast cancer each year, and receptor testing conducted on biopsied tissue typically finds that eight in 10 have estrogen receptor-positive breast cancer. Hormone receptor status can be valuable for classifying tumors and for guiding treatment, such as by identifying women who might benefit from endocrine therapy.
April 15, 2019
2019 04 15 22 17 2307 Breast Cancer 400
Previous Page
Page 3 of 3